- Chardan Capital Markets reiterates its Buy rating on gene therapy developer MeiraGTx (MGTX +14.4%) with a more bullish price target of $40 (165% upside) (from $30) after it announced a stake by a group led by Johnson & Johnson's investment arm.
- J&J does not have a presence in the areas targeted by the company, including wet AMD, radiation-induced xerostomia, Sjogren's syndrome, advanced Parkinson's and ALS.
Chardan bullish on MeiraGTx after JNJ investment; shares up 14%
Recommended For You
More Trending News
About MGTX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MGTX | - | - |
MeiraGTx Holdings plc |